

August 14, 2024

To, **Listing Department National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051

Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Symbol: MEDIASSIST

Scrip Code: 544088

#### Subject: Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith investor presentation of the Company titled:

#### "Medi Assist Healthcare Services Limited - Investor Presentation Q1 FY 25"

Kindly take the same on record.

Yours faithfully, For Medi Assist Healthcare Services Limited

Simmi Singh Bisht Chief Compliance Officer & Company Secretary

Encl: As Above

Medi Assist Healthcare Services Limited

CIN – L74900KA2000PLC027229 **Registered Office** : Tower "D", 4th Floor, IBC Knowledge Park, 4/1, Bannerghatta Road, Bengaluru - 560 029. Phone : +91 - 80 - 6919 0000. Email : ask@mediassist.in web : www.mediassist.in



# Medi Assist Healthcare Services Limited

# Investor Presentation QI FY25



# Disclaimer



By attending the meeting where this presentation or accompanying slides ("Presentation") is presented, or by reading the Presentation materials, you agree to be bound by the limitations contained herein and to maintain absolute confidentiality regarding the information disclosed in this Presentation. This Presentation contains selected information about the activities of Medi Assist Healthcare Services Limited (the "Company") and its subsidiaries and affiliates (together, the "Group") as at the date of the presentation. It does not purport to present a comprehensive overview of the Group or contain all the information necessary to evaluate an investment in the Company. This Presentation is for information purposes only and is not intended to be an advertisement and does not constitute or form part of and should not be construed as any offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with or act as an inducement to enter into any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.


The information set out herein may be subject to completion, revision, verification and amendment and such information may change materially. This Presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. The Company, or any of its affiliates, shareholders, directors, employees, agents, officers, advisors or representatives (together, "Representatives") make any express or implied representations or warranties as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein, and none of them shall have any responsibility or liability whatsoever (for negligence or otherwise, including any third party liability) for any loss or damage (including consequential loss or damage) howsoever arising from any use, reliance or distribution of this Presentation or its contents or otherwise arising in connection with this Presentation. The information set out herein is provided only as at the date of this Presentation (unless stated otherwise), its accuracy is not guaranteed, and it is subject to completion, revision, verification and amendment without notice and such information may change materially. This presentation. It should be understood that subsequent developments which may occur after the date of the information on tained in the Presentation. It should be understood that subsequent developments may affect the information or prospects of the Company. This presentation has not been and will not be updated or approved by any statutory or regulatory and you may not rely on these materials as providing, a complete or comprehensive analysis of the financial or trading position or prospects of the Company. This Presentation has not been and will not be reviewed or approved by any statutory or regulatory and you may not rely on these of investigations and analysis of the Company. This Presentation has not been and will not be reviewed or approved by any statutory or regulatory and rely on t

This Presentation contains certain "forward looking statements" relating to the business, financial performance, strategy and results of the Company and/or the industry in which it operates. Forward-looking statements are statements concerning future circumstances and results, and any other statements that are not historical facts, generally identified by the words "aim", "anticipate", "believe", "expect", "estimate", "intend", "likely to", "objective", "plan", "project", "propose", "will", "will continue", "seek to", "will pursue" or other words or phrases of similar import. All such forward looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward – looking statements are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to management. By their nature, forward – looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company.

This Presentation is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this Presentation is being provided by the Company and is subject to change without notice. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

You acknowledge that you will be solely responsible for your own assessment of the market, the market position, the business and financial condition of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company. The distribution of this Presentation in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about and observe any such restrictions.





#### Enhancing value proposition to stakeholders



Digital Customer Experience



Cybersecurity and Data Privacy



Automating and Streamlining Processes



Handling Complexity



Network Benefits



Reduce Fraud, Waste and Abuse



Advanced Data Analytics



# QI FY25 Operational highlights

### QI FY25 Operational highlights (1/2)





#### Premium under management administered – QI FY25

#### For QI FY25

• Total Premium under Management (PUM) administered is INR 5,969 crores as

on 30th June'2024, a growth of **22.4%** y-o-y

- Group PUM is INR 5,422 crs, a growth of 19.6% y-o-y
- Retail PUM is INR 547 crs, a growth of 60.1% y-o-y
- Market share in terms of health insurance premiums administered (Group + Retail), of the total health premiums in India, is 21.3% as on 30th June'2024, a growth of 40 bps y-o-y
  - Group segment market share is 30.2%, as against 30.4% as on June 30, 2023
  - Retail segment market share is 5.5%, as against 4.1% as on June 30, 2023

5

## QI FY25 Operational highlights (2/2)



#### **Business highlights**

- Maintained retention of Group accounts at 94% for Medi Assist, inclusive of Medvantage and Raksha portfolios
- I7 insurers exclusively using Medi Assist provider network across portfolio administered by the Company, a testament to the value delivered by Medi Assist to drive cashless utilization and control medical inflation
- Mayfair We Care, our international benefits business, onboarded policy holders from India with overseas health cover, thereby adding a new segment of **retail** beneficiaries to its portfolio

#### **Technology highlights**

- Facilitated over I9K Express check-outs/discharges through our Raksha
  Prime program with AI/ML and predictive models powering hospital bill estimation, a one-of-a-kind capability
- 2x growth in fraud prevention and savings delivered to insurers, driven by higher utilization of AI detection engine & data, towards improving hit rate in investigations
- Further to integration and completion of use cases, processed **live claims** through NHCX platform
- Technology and operations **enhanced** to enable/support insurers for compliance with IRDAI Circular



# QI FY25 Financial highlights

# QI FY25 Financial highlights (1/3)




**Revenue from Contracts with customers – QI FY25** INR cr 167.7 19.1% 140.8 Q1-FY24 Q1-FY25

#### For quarter ended 30<sup>th</sup> June'2024

- Total Income is **INR 172.9** crores, a growth of **18.3%** over the corresponding quarter of the previous year
- Revenue from contracts with customers excluding other income ("Operating Revenue") is INR 167.7 crores, a growth of 19.1% over the corresponding quarter of the previous year
- Revenue from contracts with customers included:
  - **9.3%** from Government business
  - 4.7% from International benefits business

# QI FY25 Financial highlights (2/3)





#### For quarter ended 30<sup>th</sup> June'2024


- EBITDA excluding other income ("Operating EBITDA") is INR 35.2 crs
  - a growth of **57.0%** y-o-y
  - a margin of **21.0%** on Operating Revenue
- Profit after tax ("PAT") for the period is INR 19.1 crs
  - a growth of **7.1%** y-o-y
  - a margin of **I I.0%** on Total Income
  - excluding impact of incremental amortization on technology investments:
    - PAT would be INR 21.3 crs
    - PAT margin would be 12.3%

# QI FY25 Financial highlights (3/3)

10



**Key Operating Metrics and Balance Sheet items** 



#Revenue from continuing operations (excluding government business) and computed for entities/businesses owned for the full financial year divided by the average headcount (excluding government business) and computed for entities/businesses owned for the full financial year



# Medi Assist Value Proposition

### **Experienced Board of Directors**





### **Dr.Vikram Jit Singh Chhatwal** Chairman and Whole Time Director









#### **Gauray Sharma**

**Vishal Gupta** 

Non-executive Nominee Director

BVP India Investors Private Limited, an affiliate of Bessemer Venture Partners

Non-Executive Nominee Director Head of India Investment Business, Investcorp India Asset Managers



# Ananda Mukerji

Independent Director Previously associated with Firstsource Solutions Limited and ICICI Bank Limited

#### **Recent awards**



'Best Organisations for Women, 2022' by the Economic Times in 2022



'Best Brands, 2021' by the Economic Times I in 2021



Certificate of Appreciation for exemplary performance under 'Chief Minister's Comprehensive Health Insurance Scheme under Ayushman Bharat - PMJAY' in 2021 (Govt. of Tamil Nadu)



India's Best TPA 2020 from Insurance Alerts in November 2020



'Dream Companies to Work for' and 'Best HR Strategy in line with business' - 2020 (Karnataka Best Employer Brands Award)

Satish V.N. Gidugu Chief Executive Officer and Whole-time

Director



### **Anil Chanana**

Independent Director

Himani Kapadia

India and Inside Ideas Group)

**Gopalan Srinivasan** 

Independent Director

Independent Director Former Chief Financial Officer, HCL Technologies Limited


Managing Director, OLIVER+ (Part of Oliver

Former Chairman cum Managing Director at

New India Assurance and United India Insurance

### **Dr. Ritu Anand**

Independent Director Former Senior Vice President, Tata Consultancy Services



© 2024 Medi Assist



1	Fastest growing segment with strong tailwinds – Health Insurance poised for ~23% growth <sup>1</sup>
2	Leadership position in India – 21% market share <sup>2</sup>
3	Consistently improving financial performance – Net Cash position of INR 270 cr post acquisitions
4	Offering a Pan India network with value proposition for insurers – Average claim size CAGR <6% <sup>3</sup>
5	<b>Strong growth in Group segment with high retention rate</b> – ~20% growth in premiums <sup>4</sup> y-o-y and 94% retention <sup>5</sup>
6	Scalable tech-enabled infrastructure – Addressing needs of the insurers, healthcare providers, the insured and the distribution
7	Proven track record of efficiently integrating acquired businesses – Driving consolidation and acquiring capabilities / relationships
8	Corporate Governance and experienced Management teams – Focused on responsibility towards stakeholders

I. Sourced from Frost & Sullivan; Indian Gross Domestic Health Insurance premium is expected to grow at 22.48% during FY22-FY28E; 2. Market share of Health insurance industry group + retail gross premium managed in India during QIFY25 (includes Raksha) 3. Cashless claims payout indicating lower than industry inflation 4. for group premiums in QIFY25 5. Medi Assist group accounts

13





Year	Business acquire	d Status
2016(1)	An ISO 9001 L2008 Centified TPA	
2018		Operationally integrated & financially consolidated
2022	A Medi Assist Company	Operationally integrated & fully consolidated in FY24
<b>2023</b> <sup>(2)</sup>	A Medi Assist Company	Merger order received, operationally integrated and fully consolidated in FY24
<b>2023</b> <sup>(2)</sup>	Raksha	Operational integration ongoing & financial consolidation partially in FY24

(1) Appointed date for the purpose of the DHS Amalgamation Scheme (2) Based on IRDAI approval for the acquisition \*TPA business of Medicare Insurance # Erstwhile UnitedHealthcare Parekh Insurance TPA Private Limited

14



# **Thank You**

# **Medi Assist Healthcare Services Limited**

### **Registered & Corporate Office**

Tower D, 4th Floor, IBC Knowledge Park, 4/1 Bannerghatta Road, Bangalore - 560 029 <u>www.mediassist.in</u>

E-mail: investor.relations@mediassist.in

